

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

## HAEMOGRAM

EDTA whole Blood

TEST	RESULT	UNIT	BIOLOGICAL REF INTERVAL
<b>HAEMOGLOBIN</b>	: 12.5	gms/dl	12.0 - 16.0
<b>RBC INDICES</b>			
Total R.B.C. Count	: 4.73	millions/cu.mm	3.8 - 5.8
Packed Cell Volume	: 39.6	%	37 - 47
M. C. V.	: 83.7	cu.micron	78 - 96
M. C. H.	: <b>26.4</b>	picogram	27 - 32
M. C. H. C.	: 31.6	g / dl	30 - 35
R. D. W.	: 14.6	%	11 - 15
<b>TOTAL W. B. C. COUNT</b>	: 6560	/cu.mm	4000 - 11000
<b>DIFFERENTIAL COUNT</b>			
Neutrophils	: 48.2	%	50 - 70
Lymphocytes	: 45.7	%	20 - 40
Eosinophils	: 0.5	%	01 - 04
Monocytes	: 5.3	%	02 - 06
Basophils	: 0.3	%	00 - 01
<b>PLATELET COUNT</b>	: 2.74	Lakh	1.5 - 4.5

authorized signatory

verify by : mukesh j

reporting Verification Time : 05/10/2021 16:58:00

report print Date/Time : 05/10/2021 18:19

---: end of report :---

**dr. d.p.kapuriya**

m.d.(path)

G 15379

**dr.khushbu chaudhari**

m.d.(path)

G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

### C - REACTIVE PROTEIN serum

PRINCIPLE : Particle enhanced turbidimetric assay

**CONCENTRATION** : **10 mg / l**

Biological Ref Interval : Less than 6 mg / l

**RESULT** : **Positive**

authorized signatory

verify by : mukesh j  
reporting Verification Time : 05/10/2021 16:58:00  
report print Date/Time : 05/10/2021 18:19  
---: end of report :---

**dr. d.p.kapuriya**  
m.d.(path)  
G 15379

**dr.khushbu chaudhari**  
m.d.(path)  
G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

**LIPID PROFILE serum**  
**APPEARANCE :**

TESTS	RESULTS	UNITS	BIOLOGICAL REF INTERVAL
CHOLESTEROL	198	mg / dl	< 200
TRIGLYCERIDES	319	mg / dl	< 200
HDL CHOLESTEROL ( Direct )	52.1	mg / dl	45 - 85
Non HDL CHOLESTEROL	146	mg / dl	
LDL CHOLESTEROL [ Direct ]	175	mg / dl	Less than 130
VLDL	64	mg / dl	upto 34
CHOL : HDL RATIO	3.8	%	2.5 - 4.5

**NCEP RISK CLASSIFICATION**

TESTS	DESIRABLE	MODERATE RISK	HIGH RISK
LDL CHOLESTEROL	< 130	130 - 160	> 160
HDL CHOLESTEROL	> 60	35 - 59	< 35
TOTAL CHOLESTEROL	< 200	200 - 239	> 240
CHOL / HDL RATIO	3.3 - 4.4	4.4 - 11	> 11
LDL / HDL RATIO	0.5 - 3.0	3.0 - 6.0	> 6.0
TRIGLYCERIDE	< 200	200 - 400	400 - 1000
APO A / APO B RATIO	> 1.2	-	< 1.3
APOLIPORPOTEIN ( a )	< 30	-	>

Desirable levels : Non-HDL cholesterol  
Less than 100 Ideal for people at high cardiac risk  
100 to 130 Ideal for people at low cardiac risk  
130 to 159 Ideal - near ideal for healthy population  
160 to 189 Mildly/borderline elevated  
190 to 219 Intermediate / moderately elevated  
More than 200 Severely elevated / very high

authorized signatory

verify by : mukesh j  
reporting Verification Time : 05/10/2021 17:39:00  
report print Date/Time : 05/10/2021 18:19  
---: end of report :---

**dr. d.p.kapuriya**  
m.d.(path)  
G 15379

**dr.khushbu chaudhari**  
m.d.(path)  
G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

## BIOCHEMICAL ANALYSIS (Serum)

### APPEARANCE :

TESTS	RESULTS	UNITS	Biological Ref Interval
S.G.P.T. ( ALT ) method : UV kinetic	27	U / L	< 40
S.G.O.T. ( AST ) method : UV kinetic	48	U / L	5 - 34
<b>S. PROTEINS</b>			
TOTAL PROTEINS method : BIURET colorimetric	6.12	gm / dl	6.0 - 7.8
ALBUMIN method : BCG colorimetric	4.17	gm / dl	Adult : 3.5 - 5.2 60 - 90yr : 3.5 - 4.6 >90yr : 2.9 - 4.5
GLOBULINS	2	gm / dl	2.3 - 3.5
A / G RATIO	2.1	%	
SERUM URIC ACID method : Enzymatic	5.1	mg / dl	M 3.5 to 7.2 F : 2.6 to 6.0
S.CREATININE method : Jafferate	1.26	mg / dl	M : 0.7 TO 1.4 F : 0.6 TO 1.1

authorized signatory

verify by : mukesh j  
reporting Verification Time : 05/10/2021 17:29:00  
report print Date/Time : 05/10/2021 18:19  
---: end of report :---

**dr. d.p.kapuriya**  
m.d.(path)  
G 15379

**dr.khushbu chaudhari**  
m.d.(path)  
G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

## LIVER FUNCTION TESTS

TESTS		RESULTS	UNITS	Biological Ref Interval
S. BILIRUBIN	TOTAL	0.5	mg / dl	0.0 - 1.0
	DIRECT	0.2	mg / dl	0.0 - 0.2
	INDIRECT	0.3	mg / dl	0.0 - 0.8
S. ALKALINE PHOSPHATASE		66	U / L	35 - 140

authorized signatory

verify by : mukesh j

reporting Verification Time : 05/10/2021 17:56:00

report print Date/Time : 05/10/2021 18:19

---: end of report :---

**dr. d.p.kapuriya**

m.d.(path)

G 15379

**dr.khushbu chaudhari**

m.d.(path)

G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

## RENAL FUNCTION TESTS

TESTS	RESULTS	UNITS	BIOLOGICAL REF INTERVAL
BLOOD UREA	29	mg / dl	15 - 40
S. CALCIUM	8.0	mg / dl	8.4 - 11.0

authorized signatory

verify by : mukesh j

reporting Verification Time : 05/10/2021 17:29:00

report print Date/Time : 05/10/2021 18:19

---: end of report :---

**dr. d.p.kapuriya**

m.d.(path)

G 15379

**dr.khushbu chaudhari**

m.d.(path)

G 21850

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

## Hb A1c - Fact file

Glycohaemoglobin is being used with increasing frequency to monitor long term blood glucose control and compliance in patient with diabetes mellitus. It provides an index of mean concentration of blood glucose ( eAG - estimated average glucose ) during the preceding two to three months. It complements more traditional measures of glucose control such as blood and urine glucose level.

The term " Glycohaemoglobin / Glycosylated haemoglobin / Hb A1c " refers to a series of minor haemoglobin components that are **stable adducts formed by haemoglobin with various sugars**. The reaction between haemoglobin and sugar is an example of a nonenzymatic condensation of glucose with free amino groups on the globin (NH2 terminal valine of B chain ). The process is slow , continuous and irreversible.

Human erythrocytes are freely permeable to glucose , **Within each erythrocyte GHb is formed from haemoglobin at the rate which depends on the ambient concentration of glucose. Higher the prevailing ambient level of blood glucose , higher the GHb**

The level of Hb A1c at any point of time is contributed to by all circulating erythrocytes , from oldest ( 120 days ) to the youngest RBCs. Hence Hb A1c is a **" weighted average " of glucose during the preceding three months** , near preceding 30 days contributes substantially more to the level of Hb A1c than do glucose level 90 -120 days earlier..

**There is very predictable relationship between Hb A1c and eAG ( estimated average glucose / weighted average glucose ).**

A formula based on linear regression analysis sponsored by ADA , EASD , IDF is  $eAG ( mg / dl ) = ( 28.7 * Hb A1c ) - 46.7$  replacing the older one  $eAG ( mg / dl ) = ( 35.6 * Hb A1c ) - 77.3$  recommended by DCCT .

**Post lunch and bedtime glucose correlate well with Hb A1c** ( data of full 7 point glucose profile by capillary blood ). Fasting glucose correlates less well and with increasing Hb A1c and average glucose ( eAG ) from 7 point profile , it underestimate both the values.

Any cause of shortened red cell survival will reduce exposure of red cells to glucose with consequent decrease in GHb values e.g. haemolytic anaemias like Hb S , Hb C Harlem , Hb E , Hb D . Chronic blood loss , Acute recent blood loss , etc.

A falsely low GHb test results are also be noted in c/o high Hb F samples . Thalassemia major , HPFH and other conditions.

( Hb F > 10 % ) . Glycated Hb F is not detected by assay as it does not contain the glycated B chain that characterizes Hb A1c.

A falsely elevated GHb test results can be caused by " labile GHb " - an acutely generated reversible nonenzymatic linked glucose intermediary product present after heavy meal .

Few medical condition may cause falsely elevated Hb A1c , like uremia , chronic excessive alcohol intake and hypertriglyceridemia.

Thalassemia minor causing imbalance between the synthesis of  $\alpha$  and  $\beta$  chain causes falsely elevated values.

Chronic iron deficiency anaemia in which there is an increased erythrocyte life span can raise GHb falsely.

Gestational diabetes may falsely increase or decrease Hb A1c

Studies even relate Hb A1c values with temperature / seasonal variation . Values are higher in cooler months and lower in warmer months ( June - July ).

## IS SPECIFIC PATIENT PREPARATION IS NECESSARY ?

In any case , **no fasting sample is required at all . Avoid alcohol intake and heavy meal before the assay**

Hb A1c results are to be reported by clinical laboratories world wide in SI units ( mmol / mol - no decimals ) or derived NGSP units ( % - one decimal ) . using IFCC - NGSP master equation,

An international expert committee that includes representatives from American Diabetes Association ( ADA ) , International

Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

Diabetes Federation ( IDF ) , and European Association for the Study of Diabetes ( EASD ) has **officially endorsed the Hb A1c as the Diagnostic test for the Diabetes . Cut off is  $\geq 6.5$**

#### WHY HB A1c IS CLINICALLY IMPORTANT

According to DCCT , a linear relationship is documented between the lowering Hb A1c / eAG and prevention of chronic complications . If Hb A1c is maintained at or about the upper level of normal , it can reduce app. 75 % retinal ( eye ) 60 % neuronal ( nervous system ) and 35 % renal ( kidney ) complications.

A reliable at-risk marker for assessing possible development of complications  
An excellent mean to assess , encourage and reinforce individual patient compliance  
An indicator for additional diagnostic tests such as Urine Microalbumin  
A meaningful Mean Blood Glucose ( MBG ) / estimated Average Glucose ( eAG ) relationship  
An useful method to judge the efficacy and effectiveness of intervention strategies.

#### WHAT ARE THE ADA RECOMMENDATIONS TO PREVENT COMPLICATED DIABETES

- \* Perform the A1c test at least two times a year in patient who are meeting treatment goals and have stable glycemic control
- \* Perform the A1c test quarterly in patient whose therapy has changed or who are not meeting glycemic control.
- \* Use of point-of-care testing for A1c allow for timely decisions on therapy changes when needed.

#### GLYCEMIC GOAL IN ADULT BY ADA.

To reduce microvascular and neuropathic complications of type 1 and type 2 diabetic patients - **below or around 7 %**

#### REFERENCES ( Data published by )

1. American Diabetic Association ( ADA )
2. Internationa Diabetic Federation ( IDF )
3. European Association for Study of Diabetes ( EASD )
4. American Association of Clinical Endocrinologist
5. National Glycohaemoglobin Standardization Programme ( NGSP )
6. Diabete Control and Complications Trial ( DCCT )
7. A Journal of Disease metabolism

authorized signatory

verify by : mukesh j

reporting Verification Time : 05/10/2021 16:47:00

report print Date/Time : 05/10/2021 18:19

---: end of report :---

**dr. d.p.kapuriya**

m.d.(path)

G 15379

**dr.khushbu chaudhari**

m.d.(path)

G 21850



Patient's Name : Subhasinidevi Unni

Ref.No. : HL-11622-21

Age/Sex : 61 Years /Female



Reg. Date : 05/10/2021 16:13

Referred by : C/o. Dr At Doorstep

Collection. Time : 05/10/2021

### Glycosylated Hb / Glycated Hb / Hb A1c

#### Method

Tina - quant

#### Interpretation ( % Glyco Hb )

> 8

Poor glycemic control

7 - 8

Fair glycemic control

6 - 6.9

Good glycemic control

< 6

Non-diabetic level / Near normal glycemia

#### Result

**6.5**

#### estimated Average Glucose ( eAG )

**139.8 mg / dl**

#### Comment

authorized signatory

verify by : mukesh j

reporting Verification Time : 05/10/2021 17:15:00

report print Date/Time : 05/10/2021 18:19

---: end of report :---

**dr. d.p.kapuriya**

m.d.(path)

G 15379

**dr.khushbu chaudhari**

m.d.(path)

G 21850